FDA approves Treatment for: Irritable Bowel Syndrome with Diarrhea (IBS-D)

Viberzi Generic Name: eluxadolineDate of Approval: May 27, 2015Company: Actavis plc Treatment for: Irritable Bowel Syndrome with Diarrhea (IBS-D) Viberzi is a first in class treatment for irritable bowel syndrome with diarrhea, treating the characteristic symptoms of abdominal pain and diarrhea. The U.S. Food and Drug Administration (FDA) has approved Viberzi...

Read More

FDA Approves Orkambi (lumacaftor/ivacaftor) for Cystic Fibrosis

ORKAMBI Generic Name: ivacaftor and lumacaftorDate of Approval: July 2, 2015Company: Vertex Pharmaceuticals Incorporated Treatment for: Cystic Fibrosis July 2, 2015 — The U.S. Food and Drug Administration today approved the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation. Orkambi (lumacaftor...

Read More

FDA Approves Entresto

July 7, 2015 — The U.S. Food and Drug Administration today approved Entresto(sacubitril/valsartan) tablets for the treatment of heart failure. The drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure. Entresto Generic Name: sacubitril and valsartanDate of Approval: July 7, 2015Company: Novartis Pharmaceuticals...

Read More

FDA Approves Odomzo

Odomzo (sonidegib) Capsules Company: Novartis Pharmaceuticals CorporationDate of Approval: July 24, 2015Treatment for: Basal Cell Carcinoma Odomzo is the second hedgehog pathway inhibitor approved for the treatment of basal cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved Odomzo (sonidegib), an oral hedgehog pathway inhibitor for the...

Read More